Lonza (SGX:O6Z) posted strong performances across its CDMO business division during the first quarter of the year, according to a filing with the Singapore Exchange on Friday.
The Biologics segment showcased great momentum due to solid showing in the Mammalian and Bioconjugates divisions.
There was also a strong demand from the Cell & Gene division.
In its Outlook 2025, the pharmaceutical company expects 20% sales growth and a core EBITDA margin of about 30%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.